Phentermine
1Provenance card
the boundary, as counts
Sources
3720 with DOI
12 strong · 17 moderate · 8 weak
Compilations
12026-05-12T05:36:57.961Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
33last ruled 2026-06-04
0 awaiting a ruling
Issued documents
42026-10-19T20:33:37.650Z
notice · info card · emergency
Searches
250 with no results
queries and counts on the build
Claims checked
6541 supported
41 supported · 24 not
Correspondence
0received
consent field ships in Phase 4
Edges
238
derivations recorded for this entity
Complete over 37 sources, 1 compilation, and 33 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/phentermine/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-09-07srcChanges in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m²
- 2026-09-07srcThe long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics
- 2026-09-07srcAbuse liability assessment of atomoxetine in a drug-abusing population
- 2026-09-07srcPhentermine involvement in fatal drug overdoses in Tennessee, 2019-2022
- 2026-09-07srcEffects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- 2026-09-07srcAddiction potential of phentermine prescribed during long-term treatment of obesity
- 2026-09-07srcControlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)
- 2026-09-07srcThe cardiovascular safety of antiobesity drugs - analysis of signals in the FDA Adverse Event Report System Database
- 2026-09-07srcAnti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial
- 2026-09-07srcA systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
- 2026-09-07srcPhentermine/Topiramate for the Treatment of Adolescent Obesity
- 2026-09-07srcReal-World Use of Phentermine and Topiramate for Adolescent Obesity: Retrospective Effectiveness and Safety Analysis
- 2026-09-07srcAntidepressant and antiobesity drug-induced serotonin syndrome complicated by multiple organ injury: A case report
- 2026-09-07srcA study of abrupt phentermine cessation in patients in a weight management program
- 2026-09-07srcD1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell
- 2026-09-07srcWeight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release
- 2026-09-07srcCardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release
- 2026-09-07srcPulmonary hypertension associated with use of phentermine
- 2026-09-07srcTwo-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- 2026-09-07srcAssessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy
- 2026-09-07srcAmphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
- 2026-09-07srcPharmacologic options for the treatment of obesity
- 2026-09-07srcAutopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine
- 2026-09-07srcNoradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis
- 2026-09-07srcLong-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo
- 2026-09-07srcLong-term weight control study: conclusions
- 2026-09-07srcCentral nervous system biogenic amine targets for control of appetite and energy expenditure
- 2026-09-07srcClinical experience using appetite suppressants and SSRIs
- 2026-09-07srcPhentermine -- a 'weighty' or a dangerous substance?
- 2026-09-07srcPhentermine - PubChem Compound CID 4771
- 2026-09-07srcEffects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain
- 2026-09-07srcValvular heart disease associated with fenfluramine-phentermine
- 2026-09-07srcEffects of phentermine on striatal dopamine and serotonin release in conscious rats: in vivo microdialysis study
- 2026-09-07srcPhentermine Hydrochloride Tablets (Adipex-P) Prescribing Information
- 2026-09-07srcPhentermine free base - CAS 122-09-8 chemical identity
- 2026-09-07srcPhentermine (PIM 415) - INCHEM International Programme on Chemical Safety
- 2026-09-07srcDEA Orange Book: Alphabetical Listing of Controlled Substances
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal31 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-12revisionRevision 1
- 2026-05-12genGeneration — pipeline-v5 · with 2 morepipeline-v5
- 2026-05-12rungeneration run
The same entries, as forms: six forms.